Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Natco Pharma Limited
NATCOPHARMNATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India. Address: Natco House, Hyderabad, India, 500034
Analytics
Zielpreis von Wall Street
113 397.63 INRKGV
12.6742Dividendenrendite
0.4 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen NATCOPHARM
Dividenden-Analyse NATCOPHARM
Dividendenwachstum über 5 Jahre
12 %Kontinuierliches Wachstum
2 JahreAusschüttungsquote 5-Jahres-Durchschnitt
32 %Verlauf der Dividende NATCOPHARM
Bewertung der Aktie NATCOPHARM
Finanzen NATCOPHARM
Ergebnisse | 2019 | Dynamik |